Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.40 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | IDH2 | P48735 | 2/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313399 | 1.00 | KMT2A (0.40) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL21440521 | 1.00 | KMT2A (0.40) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL20531719 | 0.96 | KMT2A (0.39) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL18313036 | 0.96 | KMT2A (0.39) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL18313331 | 0.96 | KMT2A (0.39) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL20531809 | 0.92 | KMT2A (0.36) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL19784172 | 0.92 | KMT2A (0.36) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL21220088 | 0.92 | KMT2A (0.36) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL18312736 | 0.92 | KMT2A (0.36) | KMT2APDE4AKCNH2MEN1LMNA | |
| SCHEMBL18312806 | 0.92 | KMT2A (0.36) | KMT2APDE4AKCNH2MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107949562-B | Positive allosteric modulators of muscarinic M2 receptors | 拜耳制药股份公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | CHRM2, CHRM1, CHRM3 | KMT2A 1318/4885PDE4A 246/4885KCNH2 588/4885 |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | KMT2A 1318/4885PDE4A 246/4885KCNH2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.